Market cap of Retrophin, Inc.
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|BOH Bank of Hawaii Corporation||NYSE > Finance > Major Banks||2.93|
|BLD TopBuild Corp.||NYSE > Basic Industries > Engineering & Construction||2.93|
|BREW Craft Brew Alliance, Inc.||NASDAQ > Consumer Non-Durables > Beverages (Production/Distribution)||2.93|
|CSSE Chicken Soup for the Soul Entertainment, Inc.||NASDAQ > Consumer Services > Movies/Entertainment||2.93|
|FNV Franco-Nevada Corporation||NYSE > Basic Industries > Precious Metals||2.93|
|ACXM Acxiom Corporation||NASDAQ > Technology > EDP Services||2.93|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||2.93|
|BRACU Black Ridge Acquisition Corp.||NASDAQ > Finance > Business Services||1,482.86|
|VNCE Vince Holding Corp.||NYSE > Consumer Services > Clothing/Shoe/Accessory Stores||1,676.00|
|ANTH Anthera Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||1,690.00|
|W Wayfair Inc.||NYSE > Consumer Services > Catalog/Specialty Distribution||2,786.29|
|HYAC Haymaker Acquisition Corp.||NASDAQ||3,183.33|
|CMSS CM Seven Star Acquisition Corporation||NASDAQ > Finance > Business Services||4,865.00|